AVEXIS,INC. (NASDAQ:AVXS) Files An 8-K Regulation FD Disclosure

AVEXIS,INC. (NASDAQ:AVXS) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01 Regulation FD Disclosure.

AveXis,Inc. (the Company) is
furnishing an updated corporate presentation, which the Company
may use from time to time in conversations with investors and
analysts beginning January9, 2017. A copy of the presentation is
being furnished as Exhibit99.1 to this Current Report on Form8-K.

The information in this Item 7.01 of this Current Report on
Form8-K (including Exhibit99.1) is being furnished and shall not
be deemed filed for purposes of Section18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or
otherwise subject to the liabilities of that Section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and






Slide presentation titled Company Overview.


AveXis, Inc., formerly Biolife Cell Bank, Inc., is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either carry a mutation in their SMN1 gene or their SMN1 genes have been deleted. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels. It also focuses to develop AVXS-101 to treat additional SMA types and other treatments for rare neurological genetic diseases.

AVEXIS, INC. (NASDAQ:AVXS) Recent Trading Information

AVEXIS, INC. (NASDAQ:AVXS) closed its last trading session down -0.27 at 55.04 with 320,171 shares trading hands.

An ad to help with our costs